Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 2/20 | 0.33 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | ADH1A | P07327 | 2/20 | 0.33 |
| ▸ | ADH7 | P40394 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215390 | 0.75 | TSHR (0.39) | TSHRSMN1; SMN2ATMADH1BADH1C | |
| SCHEMBL8559839 | 0.74 | TSHR (0.35) | TSHRSMN1; SMN2ATMADH1BADH1C | |
| SCHEMBL14820781 | 0.73 | — | — | |
| SCHEMBL6931736 | 0.73 | — | — | |
| SCHEMBL3406705 | 0.71 | — | — | |
| SCHEMBL7679115 | 0.71 | TSHR (0.41) | TSHRSMN1; SMN2ATMADH1BADH1C | |
| SCHEMBL28243045 | 0.71 | — | — | |
| SCHEMBL9047606 | 0.71 | — | — | |
| SCHEMBL5707565 | 0.71 | — | — | |
| SCHEMBL4396238 | 0.71 | CYP3A4 (0.42) | TSHRSMN1; SMN2ATMCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061736-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| WO-2021071837-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061736-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | TSHR 472/4885SMN1; SMN2 1661/4885ATM 4104/4885 |
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | TSHR 472/4885SMN1; SMN2 1661/4885ATM 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.